# Shock & ECMO Protocols with Virtua Voorhees Addenda

**Primary Guideline:** Surviving Sepsis Campaign 2021 Guidelines for Management of Sepsis and Septic Shock
**Official Source:** https://www.survivingsepsis.org/guidelines/adult-patients
**Supporting Guidelines:**
- American Heart Association Scientific Statement on Cardiogenic Shock 2020
- Extracorporeal Life Support Organization (ELSO) Guidelines 2022

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["Shock Recognition<br/>MAP <65 or Lactate >2"] --> B["Initial Stabilization<br/>O2, IV Access, Monitors"]
    
    B --> C["Fluid Resuscitation<br/>30 mL/kg Crystalloid Bolus"]
    
    C --> D{"Fluid<br/>Responsive?"}
    
    D -->|YES| E["Continue Fluids<br/>Reassess Response"]
    D -->|NO| F["Identify Shock Type<br/>Clinical + POCUS"]
    
    E --> G{"MAP â‰¥65<br/>Achieved?"}
    F --> G
    
    G -->|YES| H["Monitor & Treat<br/>Underlying Cause"]
    G -->|NO| I{"Shock Type<br/>Classification"}
    
    I -->|DISTRIBUTIVE| J["Norepinephrine<br/>Cultures + Antibiotics"]
    I -->|CARDIOGENIC| K["Inotropes + Consider<br/>Mechanical Support"]
    I -->|HYPOVOLEMIC| L["Blood Products<br/>Source Control"]
    I -->|OBSTRUCTIVE| M["Immediate Intervention<br/>Decompress/Anticoag"]
    
    J --> N{"Adequate<br/>Response?"}
    K --> O{"SCAI Shock<br/>Stage?"}
    L --> P{"Bleeding<br/>Controlled?"}
    M --> Q["Monitor Response<br/>to Intervention"]
    
    N -->|NO| R["Vasopressor Escalation<br/>Add Vasopressin/Epi"]
    O -->|"STAGE C-E"| S["ECMO Evaluation<br/>MCS Consideration"]
    P -->|NO| T["Surgical/IR Intervention<br/>Massive Transfusion"]
    P -->|YES| U["Continue Resuscitation<br/>Monitor Response"]
    Q --> U
    
    R --> V{"Refractory<br/>Shock?"}
    S --> W["Transfer Center<br/>Mobile ECMO Activation"]
    T --> U
    
    V -->|YES| W
    V -->|NO| U
    
    W --> X["Mobile ECMO Team<br/>Deployment"]
    X --> Y["ECMO Cannulation<br/>ICU Management"]
    
    style A fill:#ffcccc
    style B fill:#ffe6cc
    style J fill:#fff2cc
    style S fill:#ccffcc
    style W fill:#e6ccff
    style Y fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM

### Card 0 â€“ Shock Recognition & Initial Stabilization (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ SHOCK PROTOCOL ACTIVATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Recognition criteria:                â”‚
â”‚ â€¢ MAP <65 mmHg                         â”‚
â”‚ â€¢ Lactate >2 mmol/L                    â”‚
â”‚ â€¢ Signs of hypoperfusion               â”‚
â”‚ â€¢ Altered mental status                â”‚
â”‚                                         â”‚
â”‚ ğŸš€ Immediate actions (<5 minutes):      â”‚
â”‚ â€¢ High-flow oxygen                     â”‚
â”‚ â€¢ Large-bore IV access Ã— 2             â”‚
â”‚ â€¢ Continuous monitoring                â”‚
â”‚ â€¢ Arterial line consideration          â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Essential labs:                      â”‚
â”‚ â€¢ Lactate, CBC, BMP                    â”‚
â”‚ â€¢ Blood cultures Ã— 2 (before abx)      â”‚
â”‚ â€¢ ABG, PT/INR, troponin               â”‚
â”‚                                         â”‚
â”‚ [Next: Fluid resuscitation â–¶]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ Fluid Resuscitation (Node C â†’ D)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’§ FLUID RESUSCITATION PROTOCOL         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Initial fluid challenge:             â”‚
â”‚ â€¢ 30 mL/kg crystalloid bolus           â”‚
â”‚ â€¢ Balanced crystalloids preferred      â”‚
â”‚ â€¢ Rapid infusion (<30 minutes)         â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Fluid responsiveness markers:        â”‚
â”‚ â€¢ Stroke volume variation >10%         â”‚
â”‚ â€¢ Passive leg raise test positive      â”‚
â”‚ â€¢ Pulse pressure variation >13%        â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Stop criteria:                       â”‚
â”‚ â€¢ Signs of fluid overload              â”‚
â”‚ â€¢ Pulmonary edema                      â”‚
â”‚ â€¢ No hemodynamic improvement           â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Shock Recognition]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Shock Type Classification (Node F â†’ I)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” SHOCK TYPE IDENTIFICATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ©º Clinical assessment + POCUS:         â”‚
â”‚                                         â”‚
â”‚ ğŸ”´ Distributive (â†“SVR, â†‘/nl CO):        â”‚
â”‚ â€¢ Septic: infection + organ dysfunction â”‚
â”‚ â€¢ Anaphylactic: allergen exposure      â”‚
â”‚ â€¢ Neurogenic: spinal injury T6+        â”‚
â”‚                                         â”‚
â”‚ ğŸ’™ Cardiogenic (â†“CO, â†‘SVR):             â”‚
â”‚ â€¢ Acute MI, mechanical complications   â”‚
â”‚ â€¢ Arrhythmias, cardiomyopathy          â”‚
â”‚                                         â”‚
â”‚ ğŸ©¸ Hypovolemic (â†“CO, â†‘SVR):             â”‚
â”‚ â€¢ Hemorrhagic vs non-hemorrhagic       â”‚
â”‚                                         â”‚
â”‚ ğŸ« Obstructive (â†“CO, variable SVR):     â”‚
â”‚ â€¢ Tension pneumo, PE, tamponade        â”‚
â”‚                                         â”‚
â”‚ [Next: Type-specific management â–¶]     â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Fluid Response]           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ Distributive Shock Management (Node J â†’ N)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”´ DISTRIBUTIVE SHOCK - SEPSIS          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Vasopressor therapy:                 â”‚
â”‚ â€¢ Norepinephrine: 0.05-3 mcg/kg/min   â”‚
â”‚ â€¢ Target MAP â‰¥65 mmHg                  â”‚
â”‚ â€¢ Central line preferred               â”‚
â”‚                                         â”‚
â”‚ ğŸ¦  Infection control:                   â”‚
â”‚ â€¢ Blood cultures before antibiotics   â”‚
â”‚ â€¢ Broad-spectrum antibiotics <1 hour  â”‚
â”‚ â€¢ Source control evaluation           â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring parameters:               â”‚
â”‚ â€¢ Lactate clearance >10% in 2 hours   â”‚
â”‚ â€¢ ScvO2 >70% or SvO2 >65%             â”‚
â”‚ â€¢ Urine output >0.5 mL/kg/hr          â”‚
â”‚                                         â”‚
â”‚ [Next: Response evaluation â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Shock Classification]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ Cardiogenic Shock Management (Node K â†’ O)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’™ CARDIOGENIC SHOCK - SCAI STAGING     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ SCAI Shock Classification:           â”‚
â”‚ â€¢ Stage A: At risk                     â”‚
â”‚ â€¢ Stage B: Beginning                   â”‚
â”‚ â€¢ Stage C: Classic                     â”‚
â”‚ â€¢ Stage D: Deteriorating               â”‚
â”‚ â€¢ Stage E: Extremis                    â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Inotropic support:                   â”‚
â”‚ â€¢ Dobutamine: 2.5-20 mcg/kg/min       â”‚
â”‚ â€¢ Milrinone: 0.125-0.75 mcg/kg/min    â”‚
â”‚ â€¢ Avoid excessive preload reduction    â”‚
â”‚                                         â”‚
â”‚ ğŸ› ï¸ Mechanical support consideration:    â”‚
â”‚ â€¢ IABP for Stage C shock               â”‚
â”‚ â€¢ Impella for Stage D-E               â”‚
â”‚ â€¢ VA-ECMO for refractory shock         â”‚
â”‚                                         â”‚
â”‚ [Next: SCAI stage assessment â–¶]        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Shock Classification]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3C â€“ Hypovolemic Shock Management (Node L â†’ P)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ HYPOVOLEMIC SHOCK MANAGEMENT          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Volume replacement:                  â”‚
â”‚ â€¢ Crystalloids for non-hemorrhagic     â”‚
â”‚ â€¢ Blood products for hemorrhagic       â”‚
â”‚ â€¢ Aim for Hgb >7 g/dL (>10 if cardiac)â”‚
â”‚                                         â”‚
â”‚ ğŸ” Source identification:               â”‚
â”‚ â€¢ Physical examination                 â”‚
â”‚ â€¢ FAST exam for trauma                 â”‚
â”‚ â€¢ CT imaging as indicated              â”‚
â”‚                                         â”‚
â”‚ ğŸš¨ Massive transfusion protocol:        â”‚
â”‚ â€¢ Activate if >4 units in 1 hour      â”‚
â”‚ â€¢ 1:1:1 ratio PRBC:FFP:platelets      â”‚
â”‚ â€¢ Consider tranexamic acid             â”‚
â”‚                                         â”‚
â”‚ [Next: Bleeding control assessment â–¶]  â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Shock Classification]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3D â€“ Obstructive Shock Management (Node M â†’ Q)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ« OBSTRUCTIVE SHOCK INTERVENTIONS       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Cause-specific interventions:        â”‚
â”‚                                         â”‚
â”‚ ğŸ’¨ Tension pneumothorax:                â”‚
â”‚ â€¢ Immediate needle decompression       â”‚
â”‚ â€¢ Chest tube placement                 â”‚
â”‚                                         â”‚
â”‚ ğŸ«€ Cardiac tamponade:                   â”‚
â”‚ â€¢ Emergent pericardiocentesis          â”‚
â”‚ â€¢ Surgical consultation               â”‚
â”‚                                         â”‚
â”‚ ğŸ« Massive pulmonary embolism:          â”‚
â”‚ â€¢ Anticoagulation if no contraindicationsâ”‚
â”‚ â€¢ Consider thrombolysis               â”‚
â”‚ â€¢ ECMO for refractory cases           â”‚
â”‚                                         â”‚
â”‚ [Next: Monitor intervention response â–¶] â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Shock Classification]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Vasopressor Escalation (Node R â†’ V)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’‰ VASOPRESSOR ESCALATION PROTOCOL      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ”„ Escalation sequence:                 â”‚
â”‚                                         â”‚
â”‚ 1ï¸âƒ£ Norepinephrine (first-line):        â”‚
â”‚ â€¢ Start: 0.05 mcg/kg/min              â”‚
â”‚ â€¢ Max: 3 mcg/kg/min                   â”‚
â”‚                                         â”‚
â”‚ 2ï¸âƒ£ Vasopressin (add-on):               â”‚
â”‚ â€¢ Fixed dose: 0.03-0.04 units/min     â”‚
â”‚ â€¢ Do not titrate                      â”‚
â”‚                                         â”‚
â”‚ 3ï¸âƒ£ Epinephrine (third-line):           â”‚
â”‚ â€¢ Start: 0.05 mcg/kg/min              â”‚
â”‚ â€¢ Max: 2 mcg/kg/min                   â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitoring:                          â”‚
â”‚ â€¢ Arterial line mandatory             â”‚
â”‚ â€¢ Lactate q2-4h                       â”‚
â”‚                                         â”‚
â”‚ [Next: Refractory shock assessment â–¶]  â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Distributive Management]  â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ ECMO Evaluation (Node S â†’ W)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ ECMO CANDIDATE ASSESSMENT            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Inclusion criteria:                  â”‚
â”‚ â€¢ Age <75 years (relative)             â”‚
â”‚ â€¢ Refractory cardiogenic shock         â”‚
â”‚ â€¢ Potentially reversible cause         â”‚
â”‚ â€¢ Good baseline functional status      â”‚
â”‚                                         â”‚
â”‚ âŒ Exclusion criteria:                  â”‚
â”‚ â€¢ Unwitnessed cardiac arrest >10 min   â”‚
â”‚ â€¢ Irreversible end-stage disease       â”‚
â”‚ â€¢ Severe cognitive dysfunction         â”‚
â”‚ â€¢ Active malignancy with poor prognosisâ”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Current parameters to document:      â”‚
â”‚ â€¢ SCAI shock stage                     â”‚
â”‚ â€¢ Vasopressor requirements             â”‚
â”‚ â€¢ Lactate trend                       â”‚
â”‚ â€¢ Organ function                      â”‚
â”‚                                         â”‚
â”‚ [Next: Transfer center activation â–¶]   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Cardiogenic Management]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6A â€“ Mobile ECMO Activation (Node W â†’ X)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ MOBILE ECMO TEAM ACTIVATION          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš€ Transfer Center: 856-886-5111        â”‚
â”‚ Request: "Mobile ECMO consultation"     â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Information to provide:               â”‚
â”‚ â€¢ Patient age, weight, relevant historyâ”‚
â”‚ â€¢ Current shock state and interventionsâ”‚
â”‚ â€¢ Vasopressor/inotrope requirements    â”‚
â”‚ â€¢ Lactate and organ function           â”‚
â”‚                                         â”‚
â”‚ â±ï¸ Expected response times:             â”‚
â”‚ â€¢ Phone consultation: <15 minutes      â”‚
â”‚ â€¢ Team mobilization: <60 minutes       â”‚
â”‚ â€¢ Arrival at bedside: varies by locationâ”‚
â”‚                                         â”‚
â”‚ ğŸ› ï¸ Pre-arrival preparations:            â”‚
â”‚ â€¢ Continue aggressive support          â”‚
â”‚ â€¢ Obtain consent for ECMO              â”‚
â”‚ â€¢ Prepare for cannulation              â”‚
â”‚                                         â”‚
â”‚ [Next: ECMO team deployment â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: ECMO Evaluation]          â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7A â€“ ECMO Cannulation & Management (Node Y - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¥ ECMO CANNULATION & ICU MANAGEMENT     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ”§ Cannulation process:                 â”‚
â”‚ â€¢ Peripheral or central cannulation    â”‚
â”‚ â€¢ Real-time echocardiographic guidance â”‚
â”‚ â€¢ Heparin anticoagulation              â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š ECMO parameters:                     â”‚
â”‚ â€¢ Blood flow: 60-80 mL/kg/min          â”‚
â”‚ â€¢ Sweep gas: 1-2 L/min initially       â”‚
â”‚ â€¢ Target SpO2 88-95%                   â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ ICU management priorities:           â”‚
â”‚ â€¢ Hemodynamic optimization             â”‚
â”‚ â€¢ Ventilator lung-protective strategy  â”‚
â”‚ â€¢ Anticoagulation monitoring           â”‚
â”‚ â€¢ Daily weaning assessments            â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Recovery goals:                      â”‚
â”‚ â€¢ Myocardial recovery                  â”‚
â”‚ â€¢ Weaning from vasopressors            â”‚
â”‚ â€¢ Neurologic assessment                â”‚
â”‚                                         â”‚
â”‚ âœ… ECMO PROTOCOL ACTIVE                â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Mobile ECMO Activation]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7B â€“ Surgical Intervention (Node T - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”ª SURGICAL/IR INTERVENTION             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ Indications for urgent intervention: â”‚
â”‚ â€¢ Uncontrolled hemorrhage               â”‚
â”‚ â€¢ Source control needed                â”‚
â”‚ â€¢ Anatomical abnormalities             â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Immediate consultations:             â”‚
â”‚ â€¢ General surgery                      â”‚
â”‚ â€¢ Interventional radiology             â”‚
â”‚ â€¢ Specialty services as needed         â”‚
â”‚                                         â”‚
â”‚ ğŸ©¸ Massive transfusion protocol:        â”‚
â”‚ â€¢ 1:1:1 ratio maintained               â”‚
â”‚ â€¢ Factor concentrates as needed        â”‚
â”‚ â€¢ Tranexamic acid consideration        â”‚
â”‚                                         â”‚
â”‚ âœ… HEMORRHAGE CONTROL PROTOCOL ACTIVE  â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Hypovolemic Management]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7C â€“ Continued Resuscitation (Node U - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”„ CONTINUED RESUSCITATION & MONITORING  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Ongoing monitoring parameters:       â”‚
â”‚ â€¢ MAP â‰¥65 mmHg maintenance              â”‚
â”‚ â€¢ Lactate clearance >10% q2-4h         â”‚
â”‚ â€¢ Urine output â‰¥0.5 mL/kg/hr           â”‚
â”‚ â€¢ Central venous O2 saturation          â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Resuscitation goals:                 â”‚
â”‚ â€¢ Hemodynamic stability               â”‚
â”‚ â€¢ Organ perfusion restoration         â”‚
â”‚ â€¢ Resolution of hyperlactatemia        â”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Reassessment intervals:              â”‚
â”‚ â€¢ Vitals q15min until stable           â”‚
â”‚ â€¢ Labs q2-4h initially                 â”‚
â”‚ â€¢ Clinical response evaluation         â”‚
â”‚                                         â”‚
â”‚ âœ… RESUSCITATION PROTOCOL ACTIVE       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Management Pathways]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES SHOCK & ECMO ADDENDA

### **Enhanced Shock Response Program:**
- **Rapid Response Team:** Multidisciplinary approach with critical care, cardiology, pharmacy
- **Point-of-Care Ultrasound:** RUSH protocol integration for shock evaluation
- **Quality Metrics:** Time to vasopressor initiation, lactate clearance, survival outcomes
- **Mobile ECMO Program:** 24/7 availability through Transfer Center coordination

### **Shock Type-Specific Protocols:**
**Septic Shock (Most Common):**
- **Hour-1 Bundle:** Blood cultures, antibiotics, lactate, fluid resuscitation
- **Norepinephrine preferred:** First-line vasopressor with central access
- **Source control:** Aggressive evaluation and intervention

**Cardiogenic Shock:**
- **SCAI Classification:** Standardized staging for management decisions
- **Mechanical Support:** IABP, Impella, VA-ECMO available
- **Early revascularization:** PCI or surgical intervention as indicated

**Advanced Hemodynamic Monitoring:**
- **Arterial lines:** Standard for vasopressor therapy
- **Central venous access:** Required for high-dose vasopressors
- **Pulmonary artery catheters:** Selected cases of cardiogenic shock
- **Lactate trending:** Serial measurements for resuscitation guidance

### **ECMO Program Specifications:**
**Mobile ECMO Capabilities:**
- **Response Time:** <60 minutes mobilization, variable transport time
- **Cannulation Options:** Peripheral (femoral-femoral) or central approach
- **Transport Capability:** Ground and air medical transport compatible
- **ICU Management:** Dedicated ECMO team with 24/7 coverage

**ECMO Indications:**
- **Cardiogenic Shock:** SCAI Stage D-E refractory to medical therapy
- **Cardiac Arrest:** Witnessed arrest with ROSC or ongoing CPR
- **Bridge Therapy:** To definitive intervention or recovery
- **Post-cardiotomy:** Following cardiac surgical procedures

### **Quality Improvement Integration:**
- **Shock Recognition Time:** Goal <15 minutes from presentation
- **Time to Vasopressors:** Goal <1 hour for distributive shock
- **Lactate Clearance:** >10% reduction in first 2 hours
- **ECMO Activation:** Decision within 2 hours of refractory shock

### **Medication Dosing - Weight-Based Calculations:**
```
VASOPRESSOR DOSING TABLE:  
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  
â”‚ Norepinephrine (mcg/kg/min): â”‚  
â”‚ Start: 0.05 â†’ Max: 3.0 â”‚  
â”‚ 70kg patient: 3.5-210 mcg/min â”‚  
â”‚ â”‚  
â”‚ Vasopressin (fixed dose): â”‚  
â”‚ 0.03-0.04 units/min (do not titrate) â”‚  
â”‚ â”‚  
â”‚ Epinephrine (mcg/kg/min): â”‚  
â”‚ Start: 0.05 â†’ Max: 2.0 â”‚  
â”‚ 70kg patient: 3.5-140 mcg/min â”‚  
â”‚ â”‚  
â”‚ Dobutamine (mcg/kg/min): â”‚  
â”‚ Start: 2.5 â†’ Max: 20 â”‚  
â”‚ 70kg patient: 175-1400 mcg/min â”‚  
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### **Contact Information & Escalation:**
- **Transfer Center:** 856-886-5111 (Mobile ECMO activation)
- **Critical Care Attending:** Available 24/7 for consultation
- **Pharmacy:** Clinical pharmacist for dosing optimization
- **Laboratory:** STAT lactate results, blood gas analysis

### **Special Populations:**
**Pregnancy:**
- Modified hemodynamic targets
- Left lateral positioning
- Fetal monitoring considerations

**Elderly Patients:**
- ECMO candidacy evaluation
- Goals of care discussions
- Frailty assessment integration

**Pediatric Considerations:**
- Weight-based dosing protocols
- Pediatric ECMO team availability
- CHOP consultation if needed

## REFERENCE GUIDELINES
- **2021 Surviving Sepsis Campaign Guidelines**
- **2020 AHA Scientific Statement on Cardiogenic Shock**
- **2022 ELSO Guidelines for Adult ECMO**
- **Virtua Health System Shock Protocol v2025**

**This comprehensive protocol integrates current evidence-based shock management with advanced mechanical circulatory support capabilities, optimized for rapid recognition, aggressive intervention, and excellent patient outcomes at Virtua Voorhees.**
